N-(3-dimethylaminopropyl)hydrazinecarbothioamide | 27421-74-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(3-dimethylaminopropyl)hydrazinecarbothioamide
• 英文别名: 4-(3-dimethylaminopropyl)-3-thiosemicarbazide；4-(3-Dimethylaminopropyl)thiosemicarbazid；3-Amino-1-[3-(dimethylamino)propyl]thiourea；1-amino-3-[3-(dimethylamino)propyl]thiourea
• CAS: 27421-74-5
• 化学式: C₆H₁₆N₄S
• mdl: MFCD00041306
• 分子量: 176.286
• InChiKey: WNEIJHOUKWLPQA-UHFFFAOYSA-N

物化性质

• 熔点：
  78 °C
• 沸点：
  266.4±42.0 °C(Predicted)
• 密度：
  1.094±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  85.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(3-dimethylaminopropyl)hydrazinecarbothioamide 、 3-methyl-4-phenylpyridine-2-carboxaldehyde 以 乙醇 为溶剂， 反应 0.5h， 生成 1-[3-(Dimethylamino)propyl]-3-[(3-methyl-4-phenylpyridin-2-yl)methylideneamino]thiourea
  参考文献：
  名称：

  Rahman, M. F., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1980, vol. 19, # 9, p. 828 - 830

  摘要：

  DOI：
• 作为产物：
  描述：

  sodium;N-[3-(dimethylamino)propyl]carbamodithioate 在 sodium chlorite 、 肼 作用下， 以 乙醇 、 水 为溶剂， 反应 0.25h， 生成 N-(3-dimethylaminopropyl)hydrazinecarbothioamide
  参考文献：
  名称：

  Rahman, M. F., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1980, vol. 19, # 9, p. 828 - 830

  摘要：

  DOI：

文献信息

• 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as
  申请人：A. H. Robins Company, Incorporated

  公开号：US04826866A1

  公开（公告）日：1989-05-02

  A novel method of controlling epilepsy, muscle tension, muscular spasticity, and anxiety in living animal bodies by administering compounds of the formula: ##STR1## wherein: R.sup.1 is hydrogen, loweralkyl or a pharmaceutically acceptable cation; R.sup.2 and R.sup.3, same or different, are hydrogen, loweralkyl, aryl, cycloalkyl, loweralkenyl, 1-adamantyl, heterocyclicaminoalkyl, diloweralkylaminoloweralkyl, or R.sup.2 with R.sup.3 and adjacent nitrogen may form a heterocyclic ring structure; and the pharmaceutical acceptable acid salts, and tautomeric isomers thereof; and novel pharmaceutical compositions therefor are disclosed.

  一种通过给予以下式化合物来控制癫痫、肌肉紧张、肌肉痉挛和焦虑的新方法，其中：##STR1## 其中：R.sup.1 为氢、较低的烷基或药学上可接受的阳离子；R.sup.2 和 R.sup.3，相同或不同，为氢、较低的烷基、芳基、环烷基、较低的烯基、1-金刚烷基、杂环氨基烷基、二较低烷基氨基较低烷基，或 R.sup.2 与 R.sup.3 和相邻的氮原子可能形成杂环环结构；以及其药学上可接受的酸盐和互变异构体；以及相关的新型药物组合物。
• Substituted 9,10-anthracenebishydrazones
  申请人：American Cyanamid Company

  公开号：US04258181A1

  公开（公告）日：1981-03-24

  This disclosure describes anthracene-9,10-bis-carbonyl-hydrazones and derivatives thereof useful as antibacterial agents, for inhibiting the growth of transplanted mouse tumors, and for inducing the regression and/or palliation of leukemia and related cancers.

  本公开描述了蒽-9,10-双酰肼和其衍生物，可用作抗菌剂，用于抑制移植小鼠肿瘤的生长，并用于诱导白血病和相关癌症的退缩和/或缓解。
• 2-(substituted methylidene)-N-[3-[piperidin-1-yl]propyl]hydrazine
  申请人：The Rockefeller University

  公开号：US04942170A1

  公开（公告）日：1990-07-17

  The present invention relates to the treatment of diseases caused by invading organisms in a host by first identifying an enzymatic difference between the host and the invading organism and then administering to the host a pharmaceutically effective amount of a subversive substrate for the differing enzyme of the invading organism, whereby the action of the differing enzyme causes a result counter to the intended result and function of the enzyme that results in its debilitation or death. In particular, treatment of parasitic diseases caused by kinetoplastids including trypanosomes and leishmanias, e.g., African sleeping sickness, Chagas' disease, oriental sore and kala-azar is accomplished by administration of a pharmaceutically effective antiparasitic amount of a competitive toxigenic substrate for trypanothione reductase. Methods of treatment and compositions therefor contain a competitive toxigenic substrate for trypanothione reductase. Numerous compounds and corresponding compositions are disclosed.

  本发明涉及通过首先识别宿主和侵入性生物之间的酶差异，然后向宿主施用对侵入性生物不同酶的颠覆性底物的药效有效量，从而导致不同酶的作用产生与酶预期结果和功能相反的结果，并导致其衰弱或死亡，来治疗侵入性生物引起的疾病。特别是，通过施用对于抗胞内三硫磷脂还原酶具有竞争性毒素底物的药效有效抗寄生虫量，治疗由节肢动物引起的寄生虫病，包括锥虫病、利什曼病，例如非洲睡眠病、恰加斯病、东方疮和黑热病。治疗方法和组成物包含对于抗胞内三硫磷脂还原酶具有竞争性毒素底物。披露了多种化合物和相应的组成物。
• Naphthoquinone derivatives
  申请人：The Rockefeller University

  公开号：US05145975A1

  公开（公告）日：1992-09-08

  The present invention relates to the treatment of diseases caused by invading organisms in a host by first identifying an enzymatic difference between the host and the invading organism and then administering to the host a pharmaceutically effective amount of a subversive substrate for the differing enzyme of the invading organism, whereby the action of the differing enzyme causes a result counter to the intended result and function of the enzyme that results in its debilitation or death. In particular, treatment of parasitic diseases caused by kinetoplastids including trypanosomes and leishmanias, e.g., African sleeping sickness, Chagas' disease, oriental sore and kala-azar is accomplished by administration of a pharmaceutically effective antiparasitic amount of a competitive toxigenic substrate for trypanothione reductase. Methods of treatment and compositions therefor contain a competitive toxigenic substrate for trypanothione reductase. Numerous compounds and corresponding compositions are disclosed.

  本发明涉及通过首先识别宿主和入侵生物之间的酶差异，然后向宿主施用入侵生物不同酶的破坏性底物的药效量，从而导致不同酶的作用产生与预期结果和功能相反的结果，进而导致其衰弱或死亡，用于治疗入侵生物引起的疾病。特别是通过施用竞争性毒素底物的药效量来治疗由鞭毛虫类寄生虫引起的寄生虫病，包括锥虫病和利什曼病，例如非洲睡眠病、查加斯病、东方疮和黑热病。治疗方法和组成物包含竞争性毒素底物的锥虫硫胺还原酶。公开了许多化合物和相应的组成物。
• 3-Amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as
  申请人：A. H. Robins Company, Incorporated

  公开号：US04871737A1

  公开（公告）日：1989-10-03

  A novel method of controlling epilepsy, muscle tension, muscular spasticity, and anxiety in living animal bodies by administering compounds of the formula: ##STR1## wherein: R.sup.1 is hydrogen, loweralkyl or a pharmaceutically acceptable cation; R.sup.2 and R.sup.3, same or different, are hydrogen, loweralkyl, aryl, cycloalkyl, loweralkenyl, 1-adamantyl, heterocyclicaminoalkyl, diloweralkylaminoloweralkyl, or R.sup.2 with R.sup.3 and adjacent nitrogen may form a heterocyclic ring structure; and the pharmaceutical acceptable acid salts, and tautomeric isomers thereof; and novel pharmaceutical compositions therefor are disclosed.

  本发明涉及一种通过给活体动物体内注射化合物的方法来控制癫痫、肌肉紧张、肌肉痉挛和焦虑，所述化合物的结构式为：##STR1## 其中：R1为氢、低碳基或药学上可接受的阳离子；R2和R3相同或不同，为氢、低碳基、芳基、环烷基、低碳烯基、1-金刚烷基、杂环氨基烷基、二低碳基氨基低碳基，或R2与R3及相邻的氮原子可形成杂环环状结构；以及其药学上可接受的酸盐和互变异构体；以及新型的药物组合物。